Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price

The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense. 

Financial risk assessment / portfolio risk management and protection concept : Businessman holds a white umbrella, protects a dollar bag on basic balance scale, defends money from being cheat or fraud
Fintepla's $96,000 average list price is three times competing drug Epidiolex's cost • Source: Shutterstock

Zogenix Inc. won US Food and Drug Administration approval for Fintepla (fenfluramine) in the treatment of Dravet syndrome, a rare form of epilepsy that patients begin to experience in infancy, but set a list price that is three times the cost of another relatively new drug for the disease, raising questions about whether the price will limit uptake.

The US FDA approved Fintepla on 25 June for the treatment of seizures associated with Dravet syndrome in patients age...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip